Study of NS-863 for lung scarring with high blood pressure in the lungs
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests an investigational drug called NS-863 for people who have both interstitial lung disease (scarring of the lungs) and pulmonary hypertension (high blood pressure in the lungs). The goal is to see if the drug can help improve your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with interstitial lung disease (ILD) that shows on a CT scan of your chest.
- You have had a right heart catheterization (a test to measure pressure in your lungs) within the past 35 days.
- If you are taking medicines for blood pressure in the lungs or for lung scarring, they must be at a stable dose for at least 90 days.
- You are not a current smoker and have not smoked for at least 6 months.
- You are willing to use birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
This trial tests a new medication called LAM-001 for people with high blood pressure in the lungs caused by lung scarring. It aims to see if it can improve symptoms and help you feel better.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This trial tests a new medicine called NCR101 for people with interstitial lung disease (a lung condition that causes scarring). It aims to see if the drug is safe and helps slow the disease. You may be able to join if your current treatments are stable.
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Hear when a new Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.